JOSE MANUEL
BAENA CAÑADA
Investigador en el periodo 1997-2024
Publicaciones (57) Publicaciones de JOSE MANUEL BAENA CAÑADA
2024
-
Clinicopathological and Genomic Identification of Breast Cancers with No Impact on Mortality
Cancers, Vol. 16, Núm. 6
-
Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study
Journal of Nutrition, Health and Aging, Vol. 28, Núm. 8
2023
-
Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
Clinical Drug Investigation, Vol. 43, Núm. 9, pp. 691-698
-
Association between reproductive history, breast cancer subtype, and survival in premenopausal women
Medicina Clinica
-
Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
Scientific Reports, Vol. 13, Núm. 1
2022
-
Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study
Cancers, Vol. 14, Núm. 19
-
Clinicopathological characteristics and survival results of patients with ultralow risk breast cancer
Medicina Clinica, Vol. 159, Núm. 8, pp. 351-358
-
Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study
European Journal of Clinical Nutrition, Vol. 76, Núm. 9, pp. 1343-1346
2021
-
Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
Scientific Reports, Vol. 11, Núm. 1
-
Trajectories of alcohol consumption during life and the risk of developing breast cancer
British Journal of Cancer, Vol. 125, Núm. 8, pp. 1168-1176
-
Trends in Adjuvant Chemotherapy Use in Endocrine-Sensitive, HER-2 Negative Breast Cancer, with 1 to 3 Positive Nodes: A Single-Centre Study
Archives of Breast Cancer, Vol. 8, Núm. 3, pp. 233-242
2020
-
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 3, pp. 203-213
-
Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study
Scientific Reports, Vol. 10, Núm. 1
-
Serum phospholipids fatty acids and breast cancer risk by pathological subtype
Nutrients, Vol. 12, Núm. 10, pp. 1-18
2019
-
Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "sEXSAT-Q"
Health and Quality of Life Outcomes, Vol. 17, Núm. 1
-
Experiences with Prescribing Large Quantities of Systemic Anticancer Therapy near Death
Journal of Palliative Medicine, Vol. 22, Núm. 12, pp. 1515-1521
-
Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study
Scientific Reports, Vol. 9, Núm. 1
-
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125
2018
-
Adenocarcinoma de páncreas
Sanidad y Ediciones
-
Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice (Clinical and Translational Oncology, (2018), 20, 7, (862-869), 10.1007/s12094-017-1797-9)
Clinical and Translational Oncology